• Subscribe
    • Sign up for updates about the journal.
  • Sign in
  • Register
Exploration of Medicine
  • About
    • About the Journal
    • Editorial Board
    • Editorial Policies
    • Newsletter
    • Contact Us
  • Articles
    • Current Issue
    • Archives
  • Special Issue
    • All Special Issues
    • Guest Editor Guidelines
  • For Authors
    • Author Instructions
    • Editorial Process
    • Article Processing Charge
    • Submit a Manuscript
  • For Reviewers
    • Peer Review Guidelines
    • Reviewer Acknowledgment
    • To Be a Reviewer
  • Focus
  • Home
  • Exploration of Medicine
  • Special Issues
  • Special Issue Topic

    Lung Fibrosis—Models and Mechanisms

    Submission Deadline: July 31, 2023

    Guest Editor

    Prof. Bernhard Ryffel E-Mail

    Professor, INEM, UMR7355, CNRS, University of Orleans, Orleans, France

    Research Keywords: mechanisms of inflammation, innate immune danger sensing, inflammasome activation, IL-33 and Th17/Th22 differentiation


    About the Special Issue

    The lung is a critical organ for the gas exchange and health. Chronic environmental exposures may cause injury of the respiratory barrier leading to inflammation, emphysema and progressive interstitial fibrosis leading respiratory failure. We will start with an overview of human fibrotic diseases and then address the following issues:

    ● Aerosol and systemic exposure to particles, smoke, allergens, chemicals, ozone, radiation viral, bacterial, parasite and helminth infection

    ● The clinical perspectives of COPD, rodent and in vitro models, predictive for COPD?

    ● Idiopathic pulmonary fibrosis IPF and preclinical models

    ● Molecular mechanisms of fibrosis progression and cell death pathways

    ● Role of TLR, Inflammasome, DNA sensing and cross-talk of pathways

    ● InflammAging, senescence and autophagy

    ● Inflammatory cytokine such TNF and IL-1 family member, growth factors…

    ● Contribution of intestinal microbiota and metabolism such as SCFA, tryptophan serotonin…

    ● Prevention and therapy, new therapeutic targets and drug candidates

    Keywords: TNF, IL-1, growth factors, NLRP, TLR, autophagy, senescence, pollution, microbiome, metabolites, disease models

    Call for Papers

    Published Articles

    Open Access
    Perspective
    Utility of fibroblasts derived from broncho-alveolar lavage of patients with idiopathic pulmonary fibrosis or related disorders to develop in vitro models
    Broncho-alveolar lavage (BAL) represents a safe tool for the differential diagnosis of various pulmonary fibrotic diseases. Idiopathic pulmonary fibrosis (IPF) belongs to a heterogeneous group of di [...] Read more.

    Broncho-alveolar lavage (BAL) represents a safe tool for the differential diagnosis of various pulmonary fibrotic diseases. Idiopathic pulmonary fibrosis (IPF) belongs to a heterogeneous group of diseases, interstitial lung disease (ILD), presenting a progressive impairment of pulmonary functions. IPF is characterized by the excessive accumulation of extracellular matrix (ECM) in the alveolar parenchyma that may lead to irreversible pulmonary remodeling. Although the exact pathogenetic mechanisms leading to IPF development are still unclear it has been demonstrated that fibroblasts differentiating toward myofibroblasts are the major actors involved in this process. The possibility of obtaining and expanding fibroblasts from the BAL of ILD patients for research purposes has been recently explored. This approach is discussed here as a reliable chance, helpful to advance the scientific community knowledge and to devise two- and three-dimensional (2D/3D) pre-clinical in vitro models of these diseases, further overcoming technical and ethical concerns related to the use of fibroblasts derived from tissue biopsy.

    Paolo Giannoni ... Daniela de Totero
    Published: August 31, 2023 Explor Med. 2023;4:461–470
    DOI: https://doi.org/10.37349/emed.2023.00156
    Full Text
    PDF
    View:245
    Download:10
    Times Cited: 0

    Broncho-alveolar lavage (BAL) represents a safe tool for the differential diagnosis of various pulmonary fibrotic diseases. Idiopathic pulmonary fibrosis (IPF) belongs to a heterogeneous group of diseases, interstitial lung disease (ILD), presenting a progressive impairment of pulmonary functions. IPF is characterized by the excessive accumulation of extracellular matrix (ECM) in the alveolar parenchyma that may lead to irreversible pulmonary remodeling. Although the exact pathogenetic mechanisms leading to IPF development are still unclear it has been demonstrated that fibroblasts differentiating toward myofibroblasts are the major actors involved in this process. The possibility of obtaining and expanding fibroblasts from the BAL of ILD patients for research purposes has been recently explored. This approach is discussed here as a reliable chance, helpful to advance the scientific community knowledge and to devise two- and three-dimensional (2D/3D) pre-clinical in vitro models of these diseases, further overcoming technical and ethical concerns related to the use of fibroblasts derived from tissue biopsy.

    Open Access
    Original Article
    Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D
    Aim: To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but t [...] Read more.

    Aim:

    To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD).

    Methods:

    From the 218 patients recruited (ClinicalTrials.gov NCT04411446), 16 participated in this sub-study and were randomized to a single oral dose of 500,000 IU vitD (n = 10) or placebo (n = 6). Plasmatic Ang II and Ang-(1-7) levels were determined by radioimmunoassay and interleukins (ILs) 1, 6, 8, and 10 and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay before and after treatment. Parallel, serum 25-hydroxyvitamin D3 (25-OH vitD) concentrations as vitD status was measured by a chemiluminescence immunoassay.

    Results:

    A trend towards an increase in Ang-(1-7) and a decrease in Ang II levels were observed in placebo- and vitD-treated COVID-19 patients compared to baseline values. There was no difference in Ang II and Ang-(1-7) levels between placebo- and vitD-treated COVID-19 patients. Similar results were obtained with ILs profile. COVID-19 patients showed an increase in the protective component of the RAS which was not improved by vitD treatment.

    Conclusions:

    VitD did not improve RAS disbalance in COVID-19. Notwithstanding, the authors visualize that acute treatment with high doses of vitD may show a trend to a decline in inflammatory ILs and an increase in protective markers. Finally, the authors would like to highlight the limitations of this preliminary study, namely the small number of patients and the use of a large single bolus dose of vitD rather than lower daily doses for extended periods with prolonged follow-up times. All these factors need special consideration in the designs of new vitD supplementation trials. All these factors need special consideration in the designs of new vitD supplementation trials (ClinicalTrials.gov identifier: NCT04411446).

    Mauro G. Silva ... Walter Manucha
    Published: April 26, 2023 Explor Med. 2023;4:246–253
    DOI: https://doi.org/10.37349/emed.2023.00137
    Full Text
    PDF
    View:464
    Download:20
    Times Cited: 0

    Aim:

    To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD).

    Methods:

    From the 218 patients recruited (ClinicalTrials.gov NCT04411446), 16 participated in this sub-study and were randomized to a single oral dose of 500,000 IU vitD (n = 10) or placebo (n = 6). Plasmatic Ang II and Ang-(1-7) levels were determined by radioimmunoassay and interleukins (ILs) 1, 6, 8, and 10 and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay before and after treatment. Parallel, serum 25-hydroxyvitamin D3 (25-OH vitD) concentrations as vitD status was measured by a chemiluminescence immunoassay.

    Results:

    A trend towards an increase in Ang-(1-7) and a decrease in Ang II levels were observed in placebo- and vitD-treated COVID-19 patients compared to baseline values. There was no difference in Ang II and Ang-(1-7) levels between placebo- and vitD-treated COVID-19 patients. Similar results were obtained with ILs profile. COVID-19 patients showed an increase in the protective component of the RAS which was not improved by vitD treatment.

    Conclusions:

    VitD did not improve RAS disbalance in COVID-19. Notwithstanding, the authors visualize that acute treatment with high doses of vitD may show a trend to a decline in inflammatory ILs and an increase in protective markers. Finally, the authors would like to highlight the limitations of this preliminary study, namely the small number of patients and the use of a large single bolus dose of vitD rather than lower daily doses for extended periods with prolonged follow-up times. All these factors need special consideration in the designs of new vitD supplementation trials. All these factors need special consideration in the designs of new vitD supplementation trials (ClinicalTrials.gov identifier: NCT04411446).

    • Submit a Manuscript
    • Aims and Scope
    • Editorial Board
    • Author Instructions
    • Ongoing Special Issues
      Recent Advances in Hypertension
      Perspectives on Causal Mechanisms, Prevention and Management of Pediatric Obesity and Related Comorbidities
      Beyond Weed: Clinical Applications of Cannabis and Cannabinoids
      Nanomedicine and Cancer Immunotherapy
      Exploring Aortic Disease
      Role of Microbiome in Ocular Diseases
      Advances in Wound Healing
      Determinants of Exceptional Longevity
      Genetic and Epigenetic Control of Autophagy in Human Diseases
      RNA World in Health and Disease
      Lung Fibrosis—Models and Mechanisms
      Exploration of 3D and 4D Printing in the Biomedical and Personalized Medicine Fields: Merits and Challenges
      Biomaterials and Biomarkers in Dentistry: Up to Date
      Gut Microbiota Derived Metabolites and Chronic Inflammatory Diseases
      Vitamin D—Current and the Future
      Emerging Infectious Diseases
      Applications of Radiomics in Precision Medicine
      Functional Biomaterials and Tumor Immunotherapy
      Breast Cancer: Basic and Clinical Advances
      Pharmacological Agents from Mushrooms and Legumes
      Advances in the Identification and Mechanisms of Action of Luminal Compounds Involved in Inflammatory Bowel Diseases
      Spotlight on Cervical Cancer: Prevention, Early-Diagnosis, and Treatments
      Colon Controlled Microbiome Function: Role, Impact, Structure, Pathogenetic Significance, Therapeutic and Diagnostic Management
      The Role of Repetitive DNA Elements in the Development and Progression of Human Disease
      Drug Adherence in Hypertension
      Personalized Medicine in Cancer Therapy
      Standard and Emerging Treatments for Hepatocellular Carcinoma
      Novel Predictive Biomarkers and Molecular Therapeutic Targets in Urogenital Cancers
      Neurophysiological Mechanisms of Aging and Dementia
    • Completed Special Issues
      Exploring NAFLD/NASH
      Digital Biomarkers: The New Frontier for Medicine and Research
      Exploring Type 2 Diabetes Mellitus
      Angiotensins—A Century of Progress
      Exploring Chronic Liver Disease
      Reactive Oxygen Species (ROS) in Pathophysiological Conditions
      The Role of Gut Microbiota and its Metabolites in Gastrointestinal Diseases
      Disease Diagnosis, Molecular Mechanism and Therapeutic Strategies in Kidney Injury and Fibrosis
      Techniques in Repurposing and Targeted Delivery: Bringing a New Life to Shelved Drugs
      The Biological Basis of Substance Use Disorders
    • Guest Editor
    • About the Special Issue
    • Call for Papers
    • Published Articles
    • Exploration of Medicine
    • eISSN 2692-3106
    • emjournal@explorationpub.com
    • About the Journal
    • Author Instructions
    • Editorial Board
    • Editorial Policies
    • Editorial Process
    • Follow the Journal
    • JOURNALS
    • Exploration of Medicine
    • Exploration of Targeted Anti-tumor Therapy
    • Exploration of Immunology
    • Exploration of Neuroprotective Therapy
    • Exploration of Digestive Diseases
    • Exploration of Neuroscience
    • Exploration of Musculoskeletal Diseases
    • Exploration of Asthma & Allergy
    • Exploration of Drug Science
    • Exploration of Foods and Foodomics
    • Exploration of BioMat-X
    • Exploration of Digital Health Technologies
    • Exploration of Cardiology
    • Exploration of Endocrine and Metabolic Disease
    • ABOUT
    • Company Information
    • Open Access
    • Editorial Policies
    • Peer Review Policy
    • Contact Us
    • FOLLOW
    • Terms of Service Privacy Cookies
Copyright © 2023 Open Exploration Publishing Inc.